Last reviewed · How we verify
Geodon (ziprasidone)
Geodon (generic name: ziprasidone) is a Atypical antipsychotic (second-generation) Small molecule drug developed by Pfizer Inc.. It is currently FDA-approved (first approved 2001) for Agitation associated with Schizophrenia, Bipolar affective disorder, current episode manic, Bipolar disorder in remission. Also known as: Geodon, Zeldox.
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class.
Geodon, also known as ziprasidone, is an atypical antipsychotic used to treat conditions such as schizophrenia, bipolar disorder, and acute agitation in people with schizophrenia. It works by antagonizing the serotonin 2a (5-HT2a) receptor, a small molecule mechanism of action.
At a glance
| Generic name | ziprasidone |
|---|---|
| Also known as | Geodon, Zeldox |
| Sponsor | Pfizer Inc. |
| Drug class | Atypical antipsychotic (second-generation) |
| Target | Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2001-02-05 (United States) |
Mechanism of action
Ziprasidone is an atypical antipsychotic notable for causing the least weight gain and metabolic disruption among second-generation antipsychotics. It also has serotonin and norepinephrine reuptake inhibition properties, potentially beneficial for depressive symptoms. Must be taken with food (500+ calories) for adequate absorption. QTc prolongation risk requires ECG monitoring.
Approved indications
- Agitation associated with Schizophrenia
- Bipolar affective disorder, current episode manic
- Bipolar disorder in remission
- Mixed bipolar I disorder
- Schizophrenia
Boxed warnings
- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )
Common side effects
Key clinical trials
- An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis (Phase 4)
- A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications (Phase 4)
- Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder (Phase 4)
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (Phase 4)
- Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia (Phase 4)
- A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation (Phase 4)
- Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies (Phase 4)
- Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Geodon CI brief — competitive landscape report
- Geodon updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Geodon
What is Geodon?
How does Geodon work?
What is Geodon used for?
Who makes Geodon?
What is the generic name of Geodon?
Is Geodon also known as anything else?
What drug class is Geodon in?
When was Geodon approved?
What development phase is Geodon in?
What does Geodon target?
Related
- Drug class: All Atypical antipsychotic (second-generation) drugs
- Target: All drugs targeting Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Agitation associated with Schizophrenia
- Indication: Drugs for Bipolar affective disorder, current episode manic
- Indication: Drugs for Bipolar disorder in remission
- Also known as: Geodon, Zeldox
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing